A randomized, multicenter study comparing the efficacy of recombinant FSH vs recombinant FSH with Ganirelix during superovulation/IUI therapy - 25/08/11
, Jessica B. Hillard, MD a, Gary De Vane, MD b, Tim Yeko, MD c, Simon Kipersztok, MD a, Alice Rhoton-Vlasak, MD a, Chris Sistrom, MD d
Reprint requests: R. Stan Williams, MD, University of Florida, Box 100294, Gainesville, FL 32607.Abstract |
Objective |
The purpose of this study was to determine if use of a Gonadotropin releasing hormone (GnRH) antagonist, Ganirelix (Antagon), can improve pregnancy rates during superovulation with recombinant follicle-stimulating hormone (rFSH) followed by intrauterine insemination (IUI).
Study design |
This was a multicenter, prospective, randomized, open-label, assessor-blind, controlled trial of females (n=54), ages 18 to 39 undergoing superovulation/IUI with up to 4 cycles of superovulation/IUI without Ganirelix (n=66), or up to 4 cycles of superovulation/IUI with the addition of Ganirelix (n=52).
Results |
No statistically significant difference in clinical pregnancy rates per cycle initiated was found for patients in the treatment or control group (12% vs 7%, P=.29). Other variables assessed, including endometrial thickness, size of follicles, peak serum estradiol levels, mid-lutea progesterone levels, and total vials of rFSH used also showed no statistically significant difference.
Conclusion |
Superovulation/IUI cycles using Ganirelix produce similar pregnancy rates when compared with cycles not using a GnRH antagonist, although there is a trend towards better pregnancy rates in cycles with Ganirelix.
Le texte complet de cet article est disponible en PDF.Key words : Superovulation/intrauterine insemination, GnRH antagonists, Ganirelix, Antagon, Infertility, Pregnancy rate
Plan
| Presented at the Sixty-Sixth Annual Meeting of the South Atlantic Association of Obstetricians and Gynecologists, Boca Raton, Florida, January 18-21, 2004. |
Vol 191 - N° 2
P. 648-651 - août 2004 Retour au numéro
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?